ESTRO 2025 - Abstract Book

S269

Brachytherapy - Gynaecology

ESTRO 2025

Our risk-score was applied to all 104 blocks. 57 blocks were deemed to be high-risk (risk-score over 2.2), 47 blocks low risk. Three patients had residual disease at 3 months after treatment (patients EM04, EM08 and EM13). Patient EM04 had residual disease in the left cervix, EM08 was global whilst patient EM13 had residual disease in superior cervix. These regions corresponded to 16 anatomical blocks of which 15 were scored as high-risk. Blocks with residual disease had significantly higher scores than those without (p<0.05). All 57 blocks were analysed in context of brachytherapy dose distribution. When dichotomised for presence of residual disease at 3 months, blocks with residual disease had significantly lower minimum dose (p<0.02), mean dose (p<0.003), median dose (p<0.005), V100 (p<0.006), V150 (p<0.003), V200 (p<0.002) and V300 (p<0.007) than those without. Conclusion: Our adapted risk-score identifies regions of tumour at risk of having residual disease at 3 months after treatment. Whilst there were many blocks with high-risk disease, those with lower dose coverage (minimum, mean, median V100,150,200 and 300) at brachytherapy were more likely to translate into residual disease at 3 months.

Keywords: functional, MRI, dosimetry

References: 1. Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, et al. Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer. Radiotherapy and Oncology. 2022;176:17-24

3757

Digital Poster Implementing Image-Guided Brachytherapy For Cervical Cancer in Resource-Limited Settings:A Multicentre Workflow Impact Analysis from 14 Global Centres Sandra Ndarukwa 1 , Varsha Hande 2 , Aliyeva Nigar 3 , Amira Shami 4 , Blanka Jaksic 5 , Enkhtsetseg Vanchinbazar 6 , Chynara Batyrakanova 7 , Eugenia Gamboa 8 , Jickson Flores 9 , Julius Mwaisilega 10 , Maria Sucharski 11 , Sanaa Majjaoui 12 , Senem Alanyali 13 , Susan Citonje 14 , Vladyslav Sukhin 15 , Yavuz AnacaK 1 , Daniel Berger 1 , Alfredo Polo 16 , Supriya Chopra 2 1 Human Health, IAEA, Vienna, Austria. 2 Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. 3 Department of Radiation Oncology, National Centre of Oncology, Baku, Azerbaijan. 4 Department of Radiation Oncology, Institute of Nuclear Medicine and Oncology Centre, Lahore, Pakistan. 5 Department of Radiation Oncology, Clinical Hospital Center "Sister of Mercy", Zagreb, Croatia. 6 Department of Radiation Oncology, National Cancer Center of Mongolia, Ulaanbaatar, Mongolia. 7 Department of Radiation Oncology, National Center of Oncology and Hematology, Bishkek, Kyrgyzstan. 8 Department of Radiation Oncology, Instituto Oncologico Nacional Caja Petrolera de Saludrial Centre, Tiquipaya, Bolivia, Plurinational State of. 9 Department of Radiation Oncology, ose R. Reyes Memorial Medical Centertre, Manila, Philippines. 10 Department of Radiation Oncology, Ocean Road Cancer Institute, Dar es Salaam, Tanzania, United Republic of. 11 Department of Radiation Oncology, University of São Paulo, Sao Paulo, Brazil. 12 Department of Radiation Oncology, National Institute of Oncology, Rabat, Morocco. 13 Department of Radiation Oncology, Ege University Hospitalabilim Dalı, Bornova, Turkey. 14 Department of Radiation Oncology, Cancer Disease Hospital, Lusaka, Zambia. 15 Department of Radiation Oncology, Grigoriev Institute for medical Radiology and Oncology NAMS, Kharkov, Ukraine. 16 Technical Cooperation and Capacity Development, City Cancer Challenge, Geneva, Switzerland Purpose/Objective: Cervical cancer imposes a high burden in resource-limited settings due to inadequate access to brachytherapy resources( 1 ). Multi-centric studies( 2 ) and meta-analyses( 3 ) have demonstrated the superiority of image-guided brachytherapy (IGBT) over conventional brachytherapy. However, transitioning to IGBT necessitates substantial